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1  | INTRODUCTION
In 2007, a meta- analysis showed an increased cardiovascular risk 
in patients using rosiglitazone, an anti- diabetic drug.1 Here, a 
meta- analytic approach displayed its full potential: to show a side- 
effect for which individual studies were not powered. Similarly, 
the increased cardiovascular risk for rofecoxib was shown in a 
meta- analysis.2
The rosiglitazone paper was firmly debated; for example, the sta-
tistical approach was criticized.3 This highlights that meta- analyses 
are not immune to criticism, despite being conceived as high- level 
evidence. Choices in design or analysis of a review can be debated or 
criticized by readers, underlining the need for  transparent reporting.
This tutorial discusses central features of meta- analyses, includ-
ing potential misconceptions. A glossary (Table 1) provides an expla-
nation of the methodological terms used; displayed terms are shown 
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Abstract
A meta- analysis consists of a systematic approach to combine different studies in one 
design. Preferably, a protocol is written and published spelling out the research ques-
tion, eligibility criteria, risk of bias assessment, and statistical approach. Included 
studies are likely to display some diversity regarding populations, calendar period, or 
treatment settings. Such diversity should be considered when deciding whether to 
combine (some) studies in a formal meta- analysis. Statistically, the fixed effect model 
assumes that all studies estimate the same underlying true effect. This assumption is 
relaxed in a random effects model and given the expected study diversity a random 
effects approach will often be more realistic. In the absence of statistical heterogene-
ity, fixed and random effects models give identical estimates. Meta- analyses are es-
pecially useful to provide a broader scope of the literature; they should carefully 
explore sources of between study heterogeneity and may show a treatment effect or 
an exposure–outcome association where individual studies are not powered. 
However, its validity largely depends on the validity of included studies.
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Essentials
• A systematic review aims to appraise and synthesize the available evidence addressing a specific research question; a meta-analysis 
is a statistical summary of the results from relevant studies.
• A meta-analysis will provide a non-valid answer if included studies are not valid. Judgment of validity of individual studies is thus crucial.
• When deciding whether to perform a formal meta-analysis, study diversity and statistical heterogeneity should be considered.
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in the main text in italics. In Table 2, ten potential misunderstandings 
in meta-analyses are shown.
2  | RESE ARCH QUESTION AND STUDY 
PROTOCOL
Similarly to other study designs, systematic reviews start with a re-
search question to be specified in terms of population, intervention 
or risk factor, or control group and outcome(s). Defining the research 
question is a balancing act: if very narrow, the review may end up 
with few studies only (for example: effect of 40 mg simvastatin on re-
current thromboembolism in 60- to 70- year- old males); if too broad, 
a meaningful overview may be cumbersome (for example: effect of 
inflammation on coagulation). A rough idea on the number of publica-
tions on a particular topic may guide framing of the research question.
A related point is that within a systematic review framework, 
researchers are dependent on how studies are performed and re-
ported. If the effect of wine on coagulation is assessed in a review, 
some studies may report on the association between coagulation 
and alcohol in general, without providing data for wine- drinkers 
only. Such considerations should be taken into account up front 
when deciding on inclusion criteria. For the wine- coagulation ex-
ample, no formal rule will decide whether broad alcohol categories 
provide meaningful information to the review. This decision is up to 
the researchers, but arguments should be provided in the protocol 
and the paper that clarify decisions made.
It is advised to write and publish a protocol specifying details of 
design and analyses.4 The advantage prespecifying a protocol is that 
decisions will be made independently of study results.
3  | SEARCHING STUDIES AND 
EXTRACTING DATA
Many electronic databases can be used for searching studies; 
Embase, Medline, and Cochrane Library are the most well- known. 
More than one database should be searched, given the incomplete 
TABLE  1 Glossary with short explanation of technical terms used in meta- analyses
Term Explanation
Cochrane’s 
Q- test
Statistical test that examines the null- hypothesis that all studies have the same true effect.13 A significant P value provides 
evidence of statistical heterogeneity. The test is based on the deviations of study estimates from the overall mean
Fixed 
effect 
model
Statistical method to obtain a weighted average of study estimates. Studies are weighted according the inverse of the variance, 
meaning that larger studies bear more weight. The fixed effect model assumes that included studies estimate the same underly-
ing true effect
Forest plot Graphical display of effect estimates of individual studies, often presented with a weighted estimate. Forest plots display studies’ 
effect estimates and 95% confidence intervals, the weight the studies get in the meta- analysis (shown as box and/or percentage) 
and the overall weighted estimate with a 95% confidence interval
Funnel plot A funnel plot is a graphical display plotting effect estimates against sample size or inverse of the variance. The idea behind a 
funnel plot is that study effects scatter around a mean effect, but that smaller studies can deviate more from this mean. 
Publication bias may be considered if smaller studies show on average a more positive effect than larger studies. Smaller studies 
are more prone to only getting published if the result is positive, large trials tend to get published anyway. There are statistical 
techniques to judge whether these small studies show a different effect compared to larger studies18
I2 statistic Measure to quantify the amount of heterogeneity between studies that cannot be explained by chance. It is quantified as a 
percentage between 0 and 100; as a general rule low, moderate, and high heterogeneity can be assigned to I2 values of 25%, 
50%, and 75%13
Individual 
Patient 
Data (IPD) 
meta- 
Analysis
In standard meta- analyses the individual study is the unit of analysis. In an IPD meta- analysis the researchers have access to data 
at the level of individual patients from different studies. This is especially useful to harmonize endpoints and perform analyses in 
prespecified subgroups
Meta- 
regression
Statistical technique to relate study characteristics to effect estimates.19 For example the association between treatment duration 
and treatment effect for depression was studied in a meta- regression framework20
Network 
meta- 
analysis
A network meta- analysis allows the comparison of more than two groups.21 This can be a useful approach when more than two 
treatment options exist for the same indication. An example is a comparison of the thrombosis risk of different oral 
contraceptives22
Random 
effects 
model
Statistical method to obtain a weighted average of study estimates. In contrast to a fixed effect model, a random effects model 
assumes that studies have different underlying true effects. The combined effect in a random analysis is an estimation of the 
mean of these underlying true effects. Technically, the random effects model takes the between- study variation into account
Subgroup 
analysis
Restricting the statistical analysis to a group of studies based on a specific characteristic. For example, an analysis can restricted 
to randomized studies, studies with low risk of bias, or studies performed in children. Subgroup analyses can be used as a way to 
explore heterogeneity
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coverage of single databases.5 As writing database- specific search 
strings requires specific bibliographical knowledge, a search should 
be developed in collaboration with an information specialist. To op-
timize the search process, key articles should be provided to the 
information specialist, as they may contain clues to keywords and 
indexing. Additionally, references of key papers can be checked.
Inclusion of papers follows from the eligibility criteria. Data ex-
traction should be done by two researchers independently. This re-
duces the error rate, but it also may help to discuss choices to be 
made.6 For example, a paper may present effects of wine drinking 
on coagulation factors using different sets of adjusted confounders. 
Researchers have to decide which effect estimate to extract for a 
formal meta- analysis.
4  | RISK OF BIAS ANALYSIS
A meta- analysis will provide a nonvalid answer if included studies 
are not valid. The judgment of validity of individual studies is re-
ferred to as risk of bias assessment. For randomized trials risk of bias 
TABLE  2 Ten potential misunderstandings in meta- analyses
Potential misunderstanding Background
A meta- analysis is an objective procedure Every meta- analysis is characterized by decisions regarding research 
question, eligibility criteria, risk of bias analysis, and statistical 
approach. These decisions should be reasonable and transparently 
reported. Probably, no single best and ultimately objective procedure 
exists. For this reason, different meta- analyses on the same topic may 
come to different conclusions
A meta- analysis provides the highest level of evidence A meta- analysis is generally considered to provide high- level evidence. 
However, the validity of a meta- analysis depends largely on the 
validity of included studies (“garbage in—garbage out”); a meta- 
analytic design is thus not a guarantee for highest level evidence
Study quality is synonymous with risk of bias Study quality is about the question whether a study has been optimally 
performed; risk of bias relates to threats of validity. A study can be 
high quality but still have a high risk of bias for certain bias domains. 
An example is a comparison between two surgical techniques; even if 
the study is optimally performed, it cannot, by design, be blinded
A risk of bias analysis resolves the bias A risk of bias analysis mainly displays this bias risk; such a display does 
not resolve it, although a sensitivity analysis restricted to low risk of 
bias studies can be considered
Random effects models solve heterogeneity Random effects models allow that different studies have a different 
underlying true effect; the random effects model thus does not 
explain, solve, or even remove heterogeneity
Assuming homogeneity between studies when the statistical test fails 
to show heterogeneity
In the presence of few studies only, tests for heterogeneity have low 
power; the presence of a nonsignificant test does thus not provide 
strong evidence for true homogeneity between studies. This is 
especially the case if the review includes <10 studies
Present the I2 statistic as if it was a test The I2 statistic is formally not a test that can reject a null hypothesis. It 
provides a quantitative measure of the heterogeneity between 
studies beyond chance13
Assuming funnel plot symmetry when the statistical test fails to show 
heterogeneity
In the presence of few studies only, the test for heterogeneity has low 
power; the absence of a nonsignificant test does thus not provide 
strong evidence for symmetry
Funnel plot asymmetry proves publication bias Funnel plot asymmetry means that smaller studies show on average a 
different effect compared to larger studies; one explanation is 
publication bias, other explanations are effect modification and 
chance
Meta- analyses “speak for themselves” Even meta- analyses need an interpretation.16 Such an interpretation 
pertains to questions on validity, heterogeneity, and clinical 
relevance. For example, a recent review concluded that low- 
molecular- weight heparin lowered the risk of venous thromboembo-
lism in patients with lower- limb immobilization.18 The translation of 
this review to clinical practice requires a discussion whether it is 
clinically relevant to reduce thrombosis found by routine ultrasound 
screening, which was the way to assess the endpoint in most included 
papers
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assessment is standardized, and elements to be judged are conceal-
ment of allocation, blinding (participants, personnel and outcome 
assessors), selective outcome reporting, and incomplete outcome 
data.7 For these domains, researchers judge included studies for 
their risk of bias, which is reported at the study level. For exam-
ple, an unblinded study is judged “high risk of bias” with respect to 
blinding. The full risk of bias analysis is preferably tabulated to fa-
cilitate an overview and to provide an overall idea on the validity of 
included studies. Although we are actually judging risk of bias, there 
is evidence that risk of bias is related to actual bias. For example, 
unblinded studies show on average a more positive effect than ade-
quately blinded studies.8 This was shown in detail for a study assess-
ing the effect of rosiglitazone on cardiovascular endpoints, where 
the unblinded design was the likely cause of case- forms being filled 
in more often in favor of the study drug.9 As risk of bias depends 
on reporting, some elements cannot always be judged; for example, 
loss- to- follow up (potentially introducing selection bias10) is often 
poorly reported, especially in observational studies.
The crucial distinction between randomized and observational stud-
ies is the potential for confounding and judging the risk of confounding 
is key for reviews of observational studies. Confounding means that 
compared groups are different with respect to important prognos-
tic factors. In the context of interventions, this is called confounding 
by indication. It is a decision of the researchers what is considered a 
sufficient set of confounders to be adjusted for, and what statistical 
techniques are considered adequate. The mere statement that a study 
suffers from confounding because it is observational is too simplified. 
Moreover, confounding is a matter of degree. For the association be-
tween a vegetarian diet and thrombosis, the confounding will be almost 
intractable, whereas it has been shown that side effects can reliably 
be assessed in observational studies, as confounding is only marginally 
an issue.11,12 Importantly, standard statistical techniques (including pro-
pensity scores) cannot fully adjust for unmeasured confounding.
For observational studies, two other bias domains are also im-
portant. Misclassification can be of either risk factor or intervention 
under study, the outcome, or both. Selection bias refers to the bias 
introduced by selection mechanisms in studies. This type of bias 
requires methodological expertise and is often difficult to detect. 
Guidance exists for risk of bias assessment for observational studies 
on therapeutic interventions.10
Three approaches can be considered to incorporate results from 
a risk of bias analysis.
1. Researchers can restrict their meta-analysis to studies with low 
risk of bias. This is the approach for many meta-analyses on 
therapeutic interventions where observational studies are not 
eligible.
2. If risk of bias is considered too high, researchers may want to ab-
stain from statistical combining the results.
3. Exploration (by meta-regression or subgroup analyses), this ap-
proach tries to answer the question whether risk of bias influ-
ences reported effect estimates.
5  | DIVERSITY AND HETEROGENEITY
By design, a systematic review includes studies from different 
patient populations. Likely, these different populations will dis-
play diversity, for example with regard to clinical characteristics, 
study period, or health care facilities. Some diversity is thus in-
evitable. Researchers should display such between- diversity as it 
will facilitate a judgment whether included papers “tell a similar 
story.”
Statistical assessment of heterogeneity only considers the 
heterogeneity of the quantitative estimates. Such statistical mea-
sures (Cochrane’s Q-test and I2 statistic) approach the question 
of whether differences in effect estimates are beyond chance. 
Statistical tests are not powered to detect heterogeneity when 
the review includes fewer than 10 papers.13 Study diversity may 
translate into statistical heterogeneity, but this does not need 
to be the case. Researchers should thus, when thinking about 
heterogeneity and deciding whether to perform a formal meta- 
analysis, take into account both the clinical judgment and the 
statistical verdict.
6  | STATISTICAL ANALYSES
From a statistical point of view, meta- analyses are fairly sim-
ple: the pooled estimate is a weighted average of effect es-
timates of individual studies. The weighting is according to 
the inverse of the variance, which means that larger studies 
get more weight. A forest plot is a graphical display of a meta- 
analysis’ results.
Researchers have two basic statistical options to perform a meta- 
analysis: a fixed and a random effects model. The fixed effect model 
assumes that all studies have the same underlying true effect; this 
assumption is rigid (Do we really have certainty that all studies only 
differ due to chance?). A random effects model relaxes this assumption 
and does not assume that all studies have the same underlying true 
effect.
When comparing the two models, smaller studies get relatively 
more weight in a random model, and the confidence intervals are 
wider in a random effects model. This is shown in Figure 1, a graph-
ical display of both models. What is the correct model? There is 
no final answer,14 although it is often realistic to assume some un-
derlying heterogeneity and start with a random model. In case of 
absence of statistical heterogeneity, the two models give identical 
results.
Mostly, fixed and random effects models give very similar pooled 
estimates, the main difference being the wider confidence interval 
for the random model. There is an exception to this rule, when on 
average effects from smaller studies are different from effects in 
larger studies, as in Figure 1. As expected, the confidence interval 
from the fixed effect model is smaller, but there is also clear differ-
ence in pooled estimate.
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7  | PUBLICATION BIAS
Risk of bias refers to bias at the level of individual studies; publica-
tion bias distorts the overall picture. Publication bias occurs when 
studies with statistically significant positive effects are more likely 
to get published. There are many reasons for negative studies re-
maining unpublished, such as lower motivation of authors to fi-
nalize or submit negative studies, and unwillingness of journals to 
publish “uninteresting results.” Publication bias will often result in 
a too- positive picture of an intervention. This was shown for anti-
depressants, where published papers showed a 50% greater treat-
ment effect, compared to unpublished papers on the same drug.15 
Although often publication bias is considered a problem of meta- 
analyses, it is clearly a broader problem the moment a systematic 
overview is used to inform doctors, patients, and policymakers.
A funnel plot can facilitate the judgment whether publication 
bias is an issue. Publication bias may be considered if smaller 
studies show on average a more positive effect than larger 
studies.
8  | ANSWERING THE RESEARCH  
QUESTION
A systematic review provides an optimal opportunity to place 
studies in a broader context.16 Sometimes the interpretation 
of a meta- analysis is straightforward, when all studies give 
the same picture. This was the case in studies on the asso-
ciation between acromegaly and mortality, where all studies 
showed a slightly increased risk, which became significant in a 
meta- analysis.17
But in other cases the interpretation is more difficult, for example 
when one or two large trials show effects not directly comparable to 
the weighted average of a much larger number of trials. Researchers 
should than carefully balance the arguments for a decision: are the 
two large trials less likely to be biased, or is the weighted estimate 
closer to the truth?
In summary, meta- analyses are especially useful to provide 
a broader scope of the literature; they should carefully explore 
sources of between study heterogeneity, and may show a treatment 
effect or an exposure–outcome association where individual studies 
are not powered. However, its validity largely depends on validity of 
included studies.
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F IGURE  1 Graphical display of a fixed and random effects model. Forest plot showing two different statistical meta- analytic approaches 
for the same set of (fictional) studies: a fixed effect model (left) and a random effects model (right). In the forest plot effect estimates 
of individual studies, the study weights, a weighted overall effect and measures of heterogeneity (I2 statistic and a P value for the 
heterogeneity test) are shown. CI, confidence interval
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